Salt Lake City, Utah-based ZARS Pharma has received FDA approval for its topical local anesthetic peel, the firm said yesterday afternoon. The approval covers the firm's S-Caine Peel (Lidocaine and Tetracaine) cream, which is used for locally anesthetizing skin before procedures such as dermal filling, dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval is the second NDA approval the firm has received in the last year. ZARS is venture backed by CDIB, Draper Fisher Jurvetson, ePlanet Ventures, Tenex, and Wasatch Venture Fund.
posted on Friday, July 7, 2006
Related companies:
Zars
Related stories:
> ZARS In Agreement With Endo Pharmaceuticals
> ZARS Sets IPO Terms
> ZARS Pulls IPO
> Zars Files For IPO
> ZARS Expands Board
Techrockies.com Home